Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.32 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12867040 | 0.86 | GRM4 (0.36) | NTRK1MAP2K4GRM4TTK | |
| SCHEMBL7978106 | 0.84 | HTR1D (0.41) | NTRK1MAP2K4GRM4GSK3B | |
| SCHEMBL12881778 | 0.83 | NPC1 (0.40) | NTRK1MAP2K4GRM4GSK3BTTK | |
| SCHEMBL12031395 | 0.80 | JAK2 (0.50) | GSK3BMAPK1MAPKAPK2 | |
| SCHEMBL10220317 | 0.79 | NTRK1 (0.35) | NTRK1MAP2K4GRM4GSK3BMAPK1 | |
| SCHEMBL10271451 | 0.78 | MAP2K4 (0.52) | MAP2K4GSK3BMAPK1MAPKAPK2MAPKAPK3 | |
| SCHEMBL3352618 | 0.76 | GSK3B (0.51) | GRM4GSK3B | |
| SCHEMBL10271562 | 0.76 | ITK (0.43) | NTRK1MAP2K4MAPK1MAPKAPK2MAPKAPK3 | |
| SCHEMBL10271773 | 0.75 | HTR1A (0.44) | GSK3BTTK | |
| SCHEMBL7352631 | 0.74 | MAP2K4 (0.50) | MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | NTRK1 178/4885MAP2K4 4595/4885GRM4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.